Beyond Biotech - the podcast from Labiotech
Episodes
Episodes of Beyond Biotech
Mark All
Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more pre
Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.Some biop
Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosomes, and it is r
C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharm
Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adaptation o
Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies i
Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical aff
The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly im
Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline
There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fu
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Epic Bio is an epigenetic editing company, leveraging the po
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Artificial intelligence (AI) is certainly in the news consta
Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Aurion’s pipeline, and
LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic automation and synth
Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase over
The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germ
US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual selective inhibitor of
Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs).Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received orphan drug desi
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogen
Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for which there
Hearing loss is a huge – and growing – global challenge.Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant gl
June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using a
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitatin
Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact. There are few treatments for DMD, although recent advances
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us